CKPT — Checkpoint Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00- $345.11m
- $338.50m
- $0.04m
Annual balance sheet for Checkpoint Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 40.8 | 54.7 | 12.1 | 4.93 | 6.6 |
| Net Total Receivables | 0.02 | 0.017 | 0.073 | — | — |
| Prepaid Expenses | |||||
| Total Current Assets | 42.6 | 55.7 | 13.3 | 5.38 | 7.47 |
| Total Assets | 42.6 | 55.7 | 13.3 | 5.38 | 7.47 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 7.22 | 26 | 32.8 | 18.4 | 20.1 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 7.22 | 26 | 32.8 | 18.4 | 20.1 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 35.4 | 29.7 | -19.5 | -13 | -12.6 |
| Total Liabilities & Shareholders' Equity | 42.6 | 55.7 | 13.3 | 5.38 | 7.47 |
| Total Common Shares Outstanding |